Press Releases - Renalytix

RenalytixAI Partners with Capital District Physicians’ Health Plan, Inc. on KidneyIntelX™

10.17.19

Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members NEW YORK, Oct. 17, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District Physicians'

Johns Hopkins Director of Nephrology Chirag Parikh Joins RenalytixAI Board

10.14.19

NEW YORK, Oct. 14, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.

RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer

07.29.19

Company expands leadership team with focus on reimbursement for artificial intelligence clinical in vitro diagnostic, KidneyIntelX™ NEW YORK, July 29, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the

RenalytixAI Releases Positive Interim Results in Expanded Validation Study for KidneyIntelX™

07.09.19

Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease NEW YORK, July 9, 2019 /PRNewswire/ -- Renalytix AI

U.S. CPT® Code Granted for KidneyIntelX™

07.01.19

CPT Code a key component for reimbursement from private medical insurance and Medicare NEW YORK, July 1, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical

Study Published in Journal of Clinical Investigation Insight Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

06.07.19

Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need NEW YORK, June 7, 2019 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease,

RenalytixAI Expands Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

05.21.19

Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic NEW YORK, May

RenalytixAI and University Medical Center Groningen to Evaluate KidneyIntelX™ for Early Identification and Guiding Therapeutic Treatment of Diabetic Kidney Disease

05.07.19

NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500

FDA Grants Breakthrough Device Designation to KidneyIntelX™

05.02.19

Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted

RenalytixAI Forms Core Investigator Group for Kidney Transplant Advanced Diagnostic Program

03.22.19

Investigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai NEW YORK, March 22, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled